Effectiveness and Safety of Treatment With Vedolizumab in Adult Patients With Ulcerative Colitis or Crohn's Disease in Real Life
Phase of Trial: Phase IV
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms GEVOL
- Sponsors Takeda
- 27 Feb 2019 Status changed from recruiting to discontinued due to business decision and insufficient enrollement.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 28 Dec 2017 New trial record